About this item:

25 Views | 22 Downloads

Author Notes:

Hong-zhuan Chen, hongzhuan_chen@hotmail.com

Gang Wang, wg11424@rjh.com.cn

Qi Cheng, qicheng8@aliyun.com

GW, QC and HC conceived, designed and oversighted the community cohort experiments, and revised the manuscript.

YZhan and YT carried out experiments, performed statistical analyses, and wrote the manuscript.

GW, JL and YZhao conceived, designed and oversighted the clinic cohort experiments.

RR, ED and LZ conceived, designed and oversighted community cohort experiments, performed statistical analyses, and helped draft the manuscript.

All authors read and approved the final manuscript.

We sincerely thank all participating physicians from Sheshan Town Community Health Service Center in Shanghai; Dr Ge-Fei Li from the Department of Neurology; Shanghai Ninth People’s Hospital; Shanghai Jiao Tong University School of Medicine; and Dr Xiao-Juan Cheng from the Department of Neurology; Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine for assembling patients, controls and collecting samples.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.


Research Funding:

This study was supported by funds from Foundation of Collaborative Research Center for translational medicine; Shanghai Jiao Tong University School of Medicine (2015272); Natural Science Foundation of China (81371218, 81671043); a Clinical research project through Shanghai Jiao Tong University School of Medicine (No. DLY201614); and from the Shuguang Program (16SG15) supported by Shanghai Education Development Foundation; and Gaofeng Clinical Medicine Grant (20172001) supported by the Shanghai Municipal Education Commission.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Geriatrics & Gerontology
  • Neurosciences
  • Neurosciences & Neurology
  • mild cognitive impairment
  • urine
  • arginine
  • biomarker
  • early diagnosis

Dysregulated Urinary Arginine Metabolism in Older Adults With Amnestic Mild Cognitive Impairment


Journal Title:

Frontiers in Aging Neuroscience


Volume 11


, Pages 90-90

Type of Work:

Article | Final Publisher PDF


Background: Urine samples, which capture an individual's metabolic profile, are ideal for the exploration of non-invasive biomarkers to confirm the amnestic mild cognitive impairment (aMCI) status of patients vs. unimpaired ones. Objective: We aimed to detect differentially metabolized amino acids, which are important objectives in metabolomics, garnering particular attention in biomedical pathogenesis from the urine of aMCI patients, which may give clinicians the possibility to intervene with early treatments that curb Alzheimer's disease (AD). Methods: The study included 208 subjects, 98 of whom were aMCI patients, and 110 who were control subjects without dementia. Urine samples were taken from each participant and supernatant was obtained for analysis. The concentrations of amino acids were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Results: Urinary arginine levels in aMCI patients are obviously lower than in normal controls (q < 0.2 and p < 0.05). Meanwhile, aMCI patients had significant reduced urinary global arginine bioavailability ratio (GABR), and GABR in urine displayed a positive correlation with the score of CMMSE. Conclusion: Urinary dysregulated arginine metabolism that may serve as a helpful clinical diagnostic biomarker for aMCI in older adults.

Copyright information:

© 2019 Zhang, Tang, Dammer, Liu, Zhao, Zhu, Ren, Chen, Wang and Cheng.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote